October 11, 2021 09:53 AM EDT

The Endpoints 100 gives a C-suite thumbs down on 'crippling' price proposals and Aduhelm. Plus: Is anyone going to JP Morgan?

John Carroll

Editor & Founder

After tracking the opinion of the Endpoints 100 — biotech execs, mostly CEOs, who give us semi-annual feedback on key issues and trends — for the past …

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE LOG IN

The Endpoints 100 gives a C-suite thumbs down on 'crippling' price proposals and Aduhelm. Plus: Is anyone going to JP Morgan?

John Carroll

Editor & Founder

This article is available only to Premium subscribers

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Trump asks 'very tough hombre' Dr. Oz to lead MFN talks

US warns drugmakers against misrepresenting cost of imported products

Meet the ‘first sale’ rule: A customs loophole pharma companies could use to ease tariff impact

About 5% of CBER and CDER left after FDA staff cuts, analysis finds

Endpoints 100 biotech survey: Welcome to the summer of biotech’s discontent

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

The End­points 100 gives a C-suite thumbs down on 'crip­pling' price pro­pos­als and Aduhelm. Plus: Is any­one go­ing to JP Mor­gan?

Editor & Founder

This article is available only to Premium subscribers

Autonomy Bio Inc.

San Francisco, CA 94107, USA

The Endpoints 100 gives a C-suite thumbs down on 'crippling' price proposals and Aduhelm. Plus: Is anyone going to JP Morgan?